Suppr超能文献

自噬决定腺相关病毒载体肝靶向基因治疗的效率。

Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors.

作者信息

Hösel Marianna, Huber Anke, Bohlen Susanne, Lucifora Julie, Ronzitti Giuseppe, Puzzo Francesco, Boisgerault Florence, Hacker Ulrich T, Kwanten Wilhelmus J, Klöting Nora, Blüher Matthias, Gluschko Alexander, Schramm Michael, Utermöhlen Olaf, Bloch Wilhelm, Mingozzi Federico, Krut Oleg, Büning Hildegard

机构信息

Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.

German Center for Infection Research (DZIF), Partner sites Bonn-Cologne and Hannover-Braunschweig, Germany.

出版信息

Hepatology. 2017 Jul;66(1):252-265. doi: 10.1002/hep.29176. Epub 2017 May 29.

Abstract

UNLABELLED

Use of adeno-associated viral (AAV) vectors for liver-directed gene therapy has shown considerable success, particularly in patients with severe hemophilia B. However, the high vector doses required to reach therapeutic levels of transgene expression caused liver inflammation in some patients that selectively destroyed transduced hepatocytes. We hypothesized that such detrimental immune responses can be avoided by enhancing the efficacy of AAV vectors in hepatocytes. Because autophagy is a key liver response to environmental stresses, we characterized the impact of hepatic autophagy on AAV infection. We found that AAV induced mammalian target of rapamycin (mTOR)-dependent autophagy in human hepatocytes. This cell response was critically required for efficient transduction because under conditions of impaired autophagy (pharmacological inhibition, small interfering RNA knockdown of autophagic proteins, or suppression by food intake), recombinant AAV-mediated transgene expression was markedly reduced, both in vitro and in vivo. Taking advantage of this dependence, we employed pharmacological inducers of autophagy to increase the level of autophagy. This resulted in greatly improved transduction efficiency of AAV vectors in human and mouse hepatocytes independent of the transgene, driving promoter, or AAV serotype and was subsequently confirmed in vivo. Specifically, short-term treatment with a single dose of torin 1 significantly increased vector-mediated hepatic expression of erythropoietin in C57BL/6 mice. Similarly, coadministration of rapamycin with AAV vectors resulted in markedly enhanced expression of human acid-α-glucosidase in nonhuman primates.

CONCLUSION

We identified autophagy as a pivotal cell response determining the efficiency of AAVs intracellular processing in hepatocytes and thus the outcome of liver-directed gene therapy using AAV vectors and showed in a proof-of-principle study how this virus-host interaction can be employed to enhance efficacy of this vector system. (Hepatology 2017;66:252-265).

摘要

未标记

腺相关病毒(AAV)载体用于肝脏靶向基因治疗已取得显著成功,尤其是在重症B型血友病患者中。然而,达到转基因表达治疗水平所需的高载体剂量在一些患者中引发了肝脏炎症,选择性地破坏了转导的肝细胞。我们推测,通过提高AAV载体在肝细胞中的功效可以避免这种有害的免疫反应。由于自噬是肝脏对环境应激的关键反应,我们表征了肝脏自噬对AAV感染的影响。我们发现AAV在人肝细胞中诱导哺乳动物雷帕霉素靶蛋白(mTOR)依赖性自噬。这种细胞反应对于有效转导至关重要,因为在自噬受损的条件下(药理学抑制、自噬蛋白的小干扰RNA敲低或食物摄入抑制),重组AAV介导的转基因表达在体外和体内均显著降低。利用这种依赖性,我们采用自噬的药理学诱导剂来提高自噬水平。这导致AAV载体在人及小鼠肝细胞中的转导效率大大提高,与转基因、驱动启动子或AAV血清型无关,随后在体内得到证实。具体而言,用单剂量的托林1进行短期治疗显著增加了C57BL/6小鼠中载体介导的促红细胞生成素的肝脏表达。同样,雷帕霉素与AAV载体共同给药导致非人灵长类动物中人酸性α-葡萄糖苷酶的表达显著增强。

结论

我们确定自噬是决定AAV在肝细胞内加工效率的关键细胞反应,从而决定了使用AAV载体进行肝脏靶向基因治疗的结果,并在一项原理验证研究中表明如何利用这种病毒-宿主相互作用来提高该载体系统的功效。(《肝脏病学》2017年;66:252 - 265)

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b2/5518300/d45a86aa4021/HEP-66-252-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验